Journal
PATHOGENS
Volume 11, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/pathogens11060611
Keywords
HIV latency; HIV cure; cellular reservoirs; monocytes; macrophages; CNS; myeloid cells
Categories
Funding
- National Institutes of Health (NIH) [R01AI125097, R21AI157864, R01NS066801, R01NS126090, R01AG054328]
Ask authors/readers for more resources
The use of antiretroviral therapy (ART) for HIV treatment has successfully controlled plasma viremia. However, a cure for HIV is hindered by the presence of replication-competent HIV that can persist in a resting state called viral latency. This review highlights the importance of other cell types, such as monocytes and macrophages, in designing HIV cure strategies.
The use of antiretroviral therapy (ART) for Human Immunodeficiency Virus (HIV) treatment has been highly successful in controlling plasma viremia to undetectable levels. However, a complete cure for HIV is hindered by the presence of replication-competent HIV, integrated in the host genome, that can persist long term in a resting state called viral latency. Resting memory CD4+ T cells are considered the biggest reservoir of persistent HIV infection and are often studied exclusively as the main target for an HIV cure. However, other cell types, such as circulating monocytes and tissue-resident macrophages, can harbor integrated, replication-competent HIV. To develop a cure for HIV, focus is needed not only on the T cell compartment, but also on these myeloid reservoirs of persistent HIV infection. In this review, we summarize their importance when designing HIV cure strategies and challenges associated to their identification and specific targeting by the shock and kill approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available